JSPR Stock Price, Jasper Therapeutics, . Quote, Chart

Market Summary

USD23.01+0.17

Delayed

0.74%

JSPR Stock Price

View Fullscreen

JSPR RSI Chart

JSPR Valuation

Market Cap

347.1M

Price/Earnings (Trailing)

-5.43

Price/Sales (Trailing)

13.79

EV/EBITDA

-76.78

Price/Free Cashflow

-6.04

JSPR Price/Sales (Trailing)

JSPR Profitability

Return on Equity

-56.46%

Return on Assets

-50.76%

Free Cashflow Yield

-16.57%

JSPR Fundamentals

JSPR Revenue

JSPR Earnings

Earnings (TTM)

-63.9M

Earnings Growth (Yr)

3.73%

Earnings Growth (Qtr)

17.21%

Breaking Down JSPR Revenue

Last 7 days

7.9%

Last 30 days

-3.4%

Last 90 days

21.5%

Trailing 12 Months

29.3%

How does JSPR drawdown profile look like?

JSPR Financial Health

Current Ratio

13.49

JSPR Investor Care

Shares Dilution (1Y)

193.44%

Diluted EPS (TTM)

-5.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Jasper Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	mahal jeetinder singh	acquired	6,390	7.1	900	chief operating officer
Mar 12, 2024	mahal jeetinder singh	sold	-23,792	26.4358	-900	chief operating officer
Feb 08, 2024	carlyle group inc.	bought	2,460,500	12.95	190,000	-
Feb 08, 2024	velan capital investment management lp	bought	4,532,500	12.95	350,000	-
Nov 28, 2023	wiggans thomas g	bought	6,486	0.6486	10,000	-
Nov 21, 2023	wiggans thomas g	bought	6,383	0.6383	10,000	-
Nov 20, 2023	wiggans thomas g	bought	6,309	0.6309	10,000	-
Nov 17, 2023	wiggans thomas g	bought	5,966	0.5966	10,000	-
Nov 16, 2023	wiggans thomas g	bought	5,965	0.5965	10,000	-
Oct 13, 2023	lis william	sold	-6,776	0.8508	-7,965	-

Which funds bought or sold JSPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-8,844	-	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	1,230,010	1,230,010	-%
May 15, 2024	Brevan Howard Capital Management LP	new	-	245,978	245,978	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-42,739	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	3,269,710	3,269,710	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-102,478	-	-%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	new	-	684,793	684,793	0.01%
May 15, 2024	Walleye Trading LLC	added	900	1,437	2,565	-%
May 15, 2024	Boxer Capital, LLC	new	-	10,276,000	10,276,000	0.51%
May 15, 2024	Nantahala Capital Management, LLC	sold off	-100	-1,758,100	-	-%

Are Funds Buying or Selling JSPR?

Are funds buying JSPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JSPR

No. of Funds

Unveiling Jasper Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 27, 2024	avidity partners management lp	5.1%	760,000	SC 13G
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	qiming u.s. healthcare fund ii, l.p.	6.2%	928,964	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 12, 2024	carlyle group inc.	7.1%	1,066,189	SC 13D/A
Feb 09, 2024	velan capital investment management lp	7.9%	1,188,500	SC 13D/A
Feb 05, 2024	sphera funds management ltd.	6.39%	7,130,625	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	8.8%	987,096	SC 13G/A
Oct 10, 2023	sphera funds management ltd.	5.13%	5,687,134	SC 13G
Feb 27, 2023	velan capital investment management lp	7.7%	8,385,000	SC 13D

Recent SEC filings of Jasper Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 03, 2024	DEFA14A	DEFA14A
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Mar 27, 2024	SC 13G	Major Ownership Report
Mar 12, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	10-K	Annual Report

Peers (Alternatives to Jasper Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Jasper Therapeutics, Inc. News

Latest updates

Jasper Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q2	2022Q1	2019Q4
Revenue	31.0%	1,436,000	1,096,000	92,000	-	-
Operating Expenses	27.8%	17,827,000	13,947,000	11,963,000	12,778,000	-
S&GA Expenses	9.4%	4,530,000	4,142,000	3,828,000	4,590,000	-
R&D Expenses	35.6%	13,297,000	9,805,000	8,135,000	8,188,000	-
Interest Expenses	-55.7%	-109,000	-70,000	-3,000	-74,000	-
EBT Margin	-	-	-	-	-	-3.75
Net Income	-12.8%	-16,080,000	-14,260,000	-10,404,000	-2,207,000	-595,380
Net Income Margin	100.0%	-	-11.35	-	-	-3.86
Free Cashflow	-28.4%	-13,272,000	-10,335,000	-9,356,000	-14,213,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	32.7%	126	95.00	110	124	139	48.00	59.00	70.00	81.00	94.00	107	101	101	23.00	101	102	102	102
Current Assets	35.3%	120	89.00	105	119	133	42.00	52.00	63.00	74.00	88.00	102	0.00	1.00	21.00	1.00	1.00	1.00	2.00
Cash Equivalents	36.8%	119	87.00	104	116	129	38.00	51.00	61.00	71.00	85.00	101	17.00	24.00	20.00	15.00	1.00	1.00	27.00
Net PPE	-9.6%	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	3.00	4.00	3.00	3.00	-	1.00	-	-	-	-
Liabilities	-22.6%	13.00	16.00	16.00	14.00	14.00	12.00	12.00	12.00	12.00	24.00	29.00	14.00	11.00	15.00	4.00	4.00	4.00	11.00
Current Liabilities	-27.9%	9.00	12.00	12.00	9.00	8.00	7.00	7.00	7.00	6.00	8.00	9.00	0.00	0.00	4.00	0.00	0.00	0.00	0.00
Shareholder's Equity	44.4%	113	78.00	94.00	110	125	36.00	48.00	59.00	68.00	70.00	79.00	5.00	2.00	0.00	5.00	5.00	5.00	5.00
Retained Earnings	-8.1%	-183	-169	-153	-135	-119	-105	-91.92	-80.06	-69.66	-67.45	-58.39	-5.15	-1.58	-36.81	-0.44	-0.24	0.00	-0.60
Additional Paid-In Capital	19.6%	297	248	247	246	245	141	139	139	138	137	137	10.00	7.00	2.00	5.00	5.00	5.00	6.00
Shares Outstanding	35.1%	15.00	11.00	11.00	11.00	11.00	4.00	4.00	4.00	4.00	4.00	0.00	-	-	0.00	0.00	-	-	0.00
Float	-	-	-	-	111	-	-	-	49.00	-	-	-	99.00	-	-	-	103	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	4.6%	-15,736	-16,500	-11,993	-13,272	-10,335	-12,688	-9,643	-9,356	-14,213	-14,584	-7,108	-5,791	-6,195	-5,393	-12,467	-173	-232	-
Share Based Compensation	0.9%	1,169	1,158	1,395	1,391	1,267	1,604	644	1,065	778	231	195	295	327	437	316	-	-	-
Cashflow From Investing	89.1%	-25.00	-230	-	-11.00	-26.00	-82.00	-222	-243	-29.00	-711	-470	-287	-960	18.00	72.00	31.00	77.00	-
Cashflow From Financing	17572.0%	47,349	-271	36.00	-305	101,511	28.00	1.00	13.00	13.00	-909	91,726	-600	10,752	10,803	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

JSPR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 10,298	$ 9,805
General and administrative	4,774	4,142
Total operating expenses	15,072	13,947
Loss from operations	(15,072)	(13,947)
Interest income	1,386	1,096
Change in fair value of earnout liability	(20)	(764)
Change in fair value of common stock warrant liability		(575)
Other expense, net	(22)	(70)
Total other income (expense), net	1,344	(313)
Net loss and comprehensive loss	$ (13,728)	$ (14,260)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (1.03)	$ (1.62)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)	13,334,900	8,787,756

JSPR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 118,475	$ 86,887
Prepaid expenses and other current assets	1,833	2,051
Total current assets	120,308	88,938
Property and equipment, net	2,464	2,727
Operating lease right-of-use assets	1,351	1,467
Restricted cash	417	417
Other non-current assets	1,423	1,343
Total assets	125,963	94,892
Current liabilities:
Accounts payable	2,391	4,149
Current portion of operating lease liabilities	1,000	972
Earnout liability	20
Accrued expenses and other current liabilities	5,505	7,253
Total current liabilities	8,916	12,374
Non-current portion of operating lease liabilities	1,553	1,814
Other non-current liabilities	2,264	2,264
Total liabilities	12,733	16,452
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock: $0.0001 par value — 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; none issued and outstanding at March 31, 2024 and December 31, 2023
Common stock: $0.0001 par value — 492,000,000 shares authorized at March 31, 2024 and December 31, 2023; 15,085,553 and 11,163,896 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2	1
Additional paid-in capital	296,556	248,039
Accumulated deficit	(183,328)	(169,600)
Total stockholders’ equity	113,230	78,440
Total liabilities and stockholders’ equity	$ 125,963	$ 94,892

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

CEO	Mr. Ronald A. Martell
WEBSITE	jaspertherapeutics.com/
INDUSTRY	Biotechnology
EMPLOYEES	35

Jasper Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Jasper Therapeutics, Inc.? What does JSPR stand for in stocks?

JSPR is the stock ticker symbol of Jasper Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jasper Therapeutics, Inc. (JSPR)?

As of Fri May 17 2024, market cap of Jasper Therapeutics, Inc. is 347.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers.

What is the fair value of JSPR stock?

You can check JSPR's fair value in chart for subscribers. The fair value of Jasper Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jasper Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JSPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jasper Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JSPR is over valued or under valued. Whether Jasper Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Jasper Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JSPR.

What is Jasper Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, JSPR's PE ratio (Price to Earnings) is -5.43 and Price to Sales (PS) ratio is 13.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JSPR PE ratio will change depending on the future growth rate expectations of investors.